Donanemab Dosing and ARIA Risk in TRAILBLAZER-ALZ 6
Written by
Neurology Live
Published
0
comments
0
min
Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.